美股
Lead report
Ionis Licenses Zilganerse to Recordati Outside U.S. in Biotech Deal
Ionis Pharmaceuticals has signed an exclusive licensing agreement with Recordati for its rare disease drug Zilganerse, covering markets outside the United States. The deal highlights strategic risk-sharing and commercial expansion in the biopharma sector.
